-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Society News
-
Journal of Thoracic Oncology’s Impact Factor Rises Again; JTO Clinical and Research Reports Receives First Impact Factor
The IASLC’s official journal now ranks second among 100 respiratory medicine journals and 13th among 322 oncology journals.
-
In Case You Missed It: Recent News from IASLC
Submit abstracts for ACLC 2024 by June 7, register for the 2024 CT Screening Symposium, and contribute memories for the 50th anniversary time capsule.
-
IASLC Launches Global Member Survey on Diversity, Equity, and Inclusion
The association seeks input from members to better understand the current DEI landscape so it can continue to build a diverse international community dedicated to the elimination of thoracic malignancies.
-
In Case You Missed It: IASLC Launches New Education Center
Lung Cancer 360 offers a centralized hub for thoracic oncology learning opportunities spanning multiple disciplines and formats.
-
Can pCR Be an Early Clinical Trial Endpoint? Initiative Aims to Answer That Question
Dr. Mark Kris, who leads the IASLC Pathologic Response Project, recently provided an update on efforts to collect data to confirm whether pathologic complete response can predict long-term outcomes.
-
Scientist, Advocate, and Leader: A Q&A with Dr. Jennifer King
Get to know IASLC’s new Chief Science Officer and learn more about the role she and her team will play in conquering thoracic cancers in the 21st century.
-
Global Survey Aims to Provide Insights on Biomarker Testing
The IASLC seeks the lung cancer community’s input to assess the use of molecular testing—and barriers to its implementation—worldwide.
-
Multidisciplinary Team to Chair 2025 World Conference
Drs. Umberto Malapelle, Jarushka Naidoo, Isabelle Opitz, and Noemí Reguart will lead WCLC when it returns to Barcelona September 6-9, 2025.
-
IASLC Launches Multiple Initiatives as Work on its New Strategic Plan Begins
Projects—including a team science grant, an expanded IASLC Academy, and an international biomarker survey—aim to help the association meet the needs of the global lung cancer community, IASLC leaders say.
-
Abstract Submissions, Reviewer Workshop Applications Open for WCLC
The 2024 World Conference on Lung Cancer may still be months away, but with deadlines approaching, now is the time to submit scientific abstracts and applications for the JTO manuscript reviewer workshop.
View ILCN Archives
Provider Resources
Popular Articles